37412-64-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a pharmaceutical agent for its antidiabetic properties, helping to manage blood sugar levels and potentially contributing to the development of new treatments for diabetes.
1-(4-METHOXYBENZYL)-2-THIOUREA is used as an anticancer agent, leveraging its ability to target and inhibit the growth of cancer cells, making it a candidate for further research and development in oncology.
1-(4-METHOXYBENZYL)-2-THIOUREA is used as an anti-inflammatory agent, potentially aiding in the reduction of inflammation and associated symptoms, which could be beneficial in the treatment of various inflammatory conditions.
Used in Organic Synthesis:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a reagent in organic synthesis, facilitating the creation of new chemical compounds and contributing to the advancement of chemical research and development.
Used in Chemical Compound Preparation:
1-(4-METHOXYBENZYL)-2-THIOUREA is used as a building block in the preparation of other chemical compounds, indicating its utility in the synthesis of complex molecules for various applications across different industries.

InChI:InChI=1/C9H12N2OS/c1-12-8-4-2-7(3-5-8)6-11-9(10)13/h2-5H,6H2,1H3,(H3,10,11,13)

Upstream product

• 3694-57-3 1-(isothiocyanatomethyl)-4-methoxybenzene 
• 1147550-11-5 ammonium thiocyanate 
• 2393-23-9 4-methoxy-benzylamine 
• 1336-21-6 ammonium hydroxide 
• 88681-68-9 di(1H-imidazol-2-yl)methanethione 
• 566163-51-7 N-((4-methoxybenzyl)carbamothioyl)benzamide 
• 244032-72-2 [1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-thiourea 

Downstream Products

• 384858-14-4 N-[(4-methoxyphenyl)methyl]thiazole 2-amine 
• 104097-54-3 2-(4-methoxy-benzylamino)-thiazol-4-one 
• 93331-62-5 2-(4-methoxy-benzylamino)-5-phenyl-thiazol-4-one 
• 553-13-9 Zolamine 
• 1364930-40-4 1-[2-(4-methoxy-benzylamino)-4-methyl-thiazol-5-yl]-ethanone 
• 871300-47-9 1-(4-methoxy-benzyl)-2-methyl-3-thiopseudourea 
• 1353585-35-9 3-(2,3-dihydro-benzofuran-5-ylmethyl)-1-(4-methoxy-benzyl)-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 
• 1353585-37-1 3-[2-(4-fluoro-phenoxy)-ethyl]-1-(4-methoxy-benzyl)-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 
• 1353585-44-0 C₂₁H₁₉N₅O₃S₂ 
• 910114-08-8 (2-(1-(4-methoxybenzyl)-5-(4-nitrobenzyl)-1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazin-2-ylamino)ethyl)guanidine 

Relevant academic research and scientific papers

Synthesis of monosubstituted thioureas by vapour digestion and mechanochemical amination of thiocarbamoyl benzotriazoles

Thiocarbamoyl benzotriazoles, as safe and easy-to-handle isothiocyanate equivalents, were quantitatively converted to N-monosubstituted thioureas by vapour digestion synthesis under an ammonia atmosphere. This simple, but timely process provided a synthetic platform that enabled the "slow" amination reaction to be successfully transformed into a rapid one aided by mechanochemical milling. The ammonium chloride/sodium carbonate equimolar mixture allowed in situ formation of ammonia under ball-milling conditions. This novel and green approach yielded aromatic and aliphatic primary thioureas in near-quantitative isolated yields with workup entirely based on using only water. In addition, the molecular and crystal structures of selected polyaromatic primary thioureas were determined from the synchrotron powder diffraction data.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA

The present invention provides aminohydantoin anti-malarial agents. In some embodiments, these agents have the property of functions of targeting malarial aspartic proteases while at the same time having low activity against human BACE. Methods of employing such agents are also provided.

Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: Synthesis, pharmacological evaluation, and cross-target QSAR studies

Previous studies have demonstrated that clobenpropit (N-(4-chlorobenzyl)-S-[3-(4(5)-imidazolyl)propyl]isothiourea) binds to both the human histamine H3 receptor (H3R) and H4 receptor (H4R). In this paper, we describe the synthesis and pharmacological characterization of a series of clobenpropit analogs, which vary in the functional group adjacent to the isothiourea moiety in order to study structural requirements for H3R and H4R ligands. The compounds show moderate to high affinity for both the human H3R and H4R. Furthermore, the changes in the functional group attached to the isothiourea moiety modulate the intrinsic activity of the ligands at the H4R, ranging from neutral antagonism to full agonism. QSAR models have been generated in order to explain the H3R and H4R affinities.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Reductive alkylation of thioureas: A highly practical synthesis of unsymmetrical N,N′-disubstituted thioureas

A highly practical synthesis of unsymmetrical N,N′-disubstituted thioureas by the reductive alkylation of N-monosubstituted thioureas with aldehydes is described. N-Monosubstituted thioureas can in turn be synthesized by the reductive amination of thiourea with an appropriate aldehyde. This reductive alkylation methodology was also extended to carbamates.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase

Inhibition of the isoforms of nitric oxide synthase (NOS) has important applications in therapy of several diseases, including cancer. Using 1400W [N-(3-aminomethylbenzyl)acetamidine], thiocitrulline and N δ-(4,5-dihydrothiazol-2-yl)ornithine as lead compounds, series of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas were designed as inhibitors of NOS. Ring-substituted benzyl and phenyl isothiocyanates were synthesised by condensation of the corresponding amines with thiophosgene and addition of ammonia gave the corresponding thioureas in high yields. The substituted 2-amino-4,5-dihydrothiazoles were approached by two routes. Treatment of simple benzylamines with 2-methylthio-4,5-dihydrothiazole at 180 °C afforded the corresponding 2-benzylamino-4,5-dihydrothiazoles. For less nucleophilic amines and those carrying more thermally labile substituents, the 4,5-dihydrothiazoles were approached by acid-catalysed cyclisation of N-(2-hydroxyethyl)thioureas. This cyclisation was shown to proceed by an SN2-like process. Modest inhibitory activity was shown by most of the thioureas and 4,5-dihydrothiazoles, with N-(3-aminomethylphenyl)thiourea (IC50=13 μM vs rat neuronal NOS and IC50=23 μM vs rat inducible NOS) and 2-(3-aminomethylphenylamino)-4,5-dihydrothiazole (IC50=13 μM vs rat neuronal NOS and IC50=19 μM vs human inducible NOS) being the most potent. Several thioureas and 4,5-dihydrothiazoles were found to stimulate the activity of human inducible NOS in a time-dependent manner.